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Abstract
Some individuals seek to enhance their cognitive capabilities through the use of pharmacol-
ogy. Such behavior entails potential health risks and raises ethical concerns. The aim of this
study was to examine whether a precursor of behavior, ethical judgement towards the use
of existing biological cognitive enhancers (e.g., coffee, legal and illegal drugs), is shaped by
the perceived characteristics of these cognitive enhancers. Students and employees com-
pleted an online questionnaire which measured perceived characteristics of 15 substances
presented as potential cognitive enhancers and a measure of ethical judgement towards
these cognitive enhancers. Results of mixed model regression analyzes show that ethical
judgement is more favourable when cognitive enhancers are perceived as being legal, famil-
iar, efficient, and safe for users’ health, supporting all hypotheses. Results further show that
36% of variance (in the null model) lies at the level of cognitive enhancers and 21% at the
level of participants. In conclusion, cognitive enhancers vary widely in terms of ethical judge-
ment, which is explained by the perception of the mentioned characteristics. Implications
regarding prevention and policy-making are discussed.
Introduction
Cognitive enhancement (CE) refers to the use of technology to improve cognitive characteris-
tics (e.g., memory, attention) and thereby human performance [1]. As for technological inno-
vation in general, CE is often faced with skepticism [2], but also has a non-negligible fraction
of supporters among the public [3] and in the media industry [4]. Determinants of ethical sup-
port towards CE remain to be better understood. The present study examines whether ethical
judgement towards the use of existing biological cognitive enhancers (edible or drinkable sub-
stances, notably) is related to their perceived characteristics.
Ethical judgement
Ethical judgement refers to normative aspects of attitudes in terms of “ought be done” or
“ought not be done” on moral grounds [5]. Ethical aspects of CE were discussed for more than
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a decade in the literature (e.g., [6]). Experts in the field identified a number of ethical concerns
related to CE, such as attested risks to health safety [6, 7], the risk that individuals might be
coerced into using CE [6–11], the difficulty regulating the use of CE [6], the reduced authentic-
ity of performance obtained using CE [6–8], which is related to an alleged unfair advantage
that CE provides to its users in comparison to non-user [8]—a nuanced perspective on the rel-
evance of the unfairness argument is provided by [12]. Finally, unequal access to CE might fur-
ther inequality in outcomes [7]. The public shares these concerns [10]. Yet, the characteristics
that affect ethical judgement regarding the use of individual cognitive enhancers (e.g., caffeine
vs cocaine) remain largely unidentified.
Clarifying the factors which affect ethical judgement towards cognitive enhancers is impor-
tant because of the impact such judgements can have on the actions of individuals [5, 13, 14],
including on the consumption of different cognitive enhancers if any (e.g., [15, 16] but see
[17]). This issue has yet been only scarcely investigated. This is relevant in light of the health
risks potentially associated with the reliance upon CE (e.g., [18]).
Substance characteristics
Researchers investigated whether the ethical judgement of students towards CE is affected by
characteristics of fictitious cognitive enhancers–risks to health and legal status [19] using the
vignette method (see [20]). Our study extends the research carried out by [19] by (a) using par-
ticipants’ assessments of existing substances, rather than relying on the vignette method. The
vignette and survey methods complement each other. While the vignette method allows for
experimental control, it lacks ecological validity (the validity of the application of the finding
of a study in the real world). The survey method allows the investigator to study participants’
view of existing, rather than hypothetical, cognitive enhancers. As such, the survey method has
a higher ecological validity. Indeed, although some studies found convergent findings using
vignette the method and real-world assessments (e.g., [21]), doubts have been raised regarding
the ecological validity of the vignette method; (b) investigating each characteristic’s unique
contribution (above and beyond that of others) to variance in ethical judgement; (c) including
working adults in our sample; and (d) examining additional characteristics of cognitive
enhancers, selected from the literature.
The additional characteristics that we assessed are participants’ familiarity with the effects
of target cognitive enhancers and participants’ perception of the effectiveness of target cogni-
tive enhancers. Other characteristics mentioned in the literature focusing on general concerns
about CE (e.g., risk of coercion, fairness, and social equality) were not examined because we
did not expect them to bear differently on ethical judgement towards the use of individual sub-
stances, which is the focus of this study.
Hypotheses
Below, we briefly examine why each characteristic should be related to ethical judgement and
present our hypotheses.
Familiarity. Humans might be hardwired to perform more favourable judgements of tar-
gets with increased familiarity [22–24]. Such preference might be generalized, as shown by the
diversity of types of targets for which it has been demonstrated (e.g., [25–29]. In the specific
case of CE, familiarity was indeed found to be a predictor of favourable ethical judgement [30].
Hypothesis 1: Familiarity with a given cognitive enhancer is positively associated with ethical
judgment towards the use of that cognitive enhancer.
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Effectiveness versus risk. Our hypotheses concerning the favourable ethical judgement of
effective cognitive enhancers and the unfavourable ethical judgement of cognitive enhancers
assessed as entailing health risks draw on utilitarianism. Utilitarianism posits that behaviour is
to be judged by its consequences: the attainment of valued states or goals and the minimization
of suffering [31]. Utilitarianism prescribes the manner in which decisions are to be made and
judged. Theories of actual decision-making often draw on utilitarianism. For instance, Ber-
noulli’s theory of moral utility—and its development, expected utility theory—posit that indi-
viduals decide to perform behaviour that increases utility (the good consequences) and
decreases disutility (the bad consequences) [32]. Similar propositions are made in rational
choice theory (people weigh in expected utility and social pressure to determine preference
[33]) and prospect theory (under uncertainty, losses outweigh gains [34]). The association of
perceived effectiveness (utility) and behavioural preferences has been found to be robust in a
variety of domains (e.g., [35, 36]). [12] argues that a cultural focus on results is related to an
utilitarian perspective that makes the use of CE appealing. Indeed, the effectiveness of cogni-
tive enhancers is a predictor of their intended use [37]. Favourable ethical judgement might
underlie such increased use, as people act upon their normative attitudes.
Similarly, behaviour perceived as risky is generally considered undesirable, notably because
it elicits negative emotions (e.g., anxiety) and negative utility appraisals [38]. Indeed, negative
emotions lead to unfavourable ethical judgement [39]. The same is true for behaviour per-
ceived as unhealthy. On the contrary, behaviour perceived as healthy leads to favourable ethi-
cal judgement (e.g., [40–42]).
Hypothesis 2: Perceived effectiveness of the cognitive enhancer is positively associated with
ethical judgment.
Hypothesis 3: Perceived health risk of the cognitive enhancer is negatively associated with ethi-
cal judgment.
Legality. With obvious exceptions, people have internalized, through socialization, gen-
eral conventional values that include a moral obligation for all to obey the law ([13, 43]). While
some scholars have claimed that the law intrinsically creates the moral duty for citizen to fol-
low its rules (e.g., [44, 45]), others have shown that people notably rely on the law and on its
enforcement as an indicator of the values of their community, adjust their ethical judgement
of behavior on this basis and in their majority act accordingly [46–50].
Hypothesis 4: Perception of legality of the cognitive enhancer is positively associated with ethi-
cal judgment.
Method
Participants and procedure
Participants took part in an online survey. They were recruited on the campus of a Swiss uni-
versity and on the social media. Participant recruitment was performed through two major
means: Some participants were recruited through e-mails (convenience sampling), which
included a short description of the study, a link to the survey, and a request to forward the
email to their contacts. Other participants were recruited through posts on social media,
which displayed the same content as the e-mails (linkedin, facebook).”
Among the 197 participants who took part in the study, 148 (68% women; 33% students,
57% employees, 10% other), who answered all items relating to at least one cognitive enhancer,
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were included in our analyses. The average age of the participants was 30.46 years old
(SD = 11.06; 13 missing values). The participants were asked to assess 15 individual cognitive
enhancers on several characteristics. Examples of cognitive enhancers include: Adderall,
Amphetamines, Caffeine (e.g., coffee, tea), Methylphenidate (e.g., Ritalin), Tyrosine. The full
list is presented in the Appendix. The cognitive enhancers were selected on the basis of their
recurrence in the literature, specialized blogs and internet forums; and, for over-the-counter
supplements, availability to the Swiss population.
This study was performed in compliance with the Declaration of Helsinki and the guide-
lines of the Swiss Psychological Society. Participation was voluntary and no compensation was
offered for participating. An informed consent page was included on the first page of the ques-
tionnaire. Only participants who gave their informed consent were able to take part in the
study. On the informed consent page, participants were informed that the aim of the study was
to understand how cognitive enhancement was viewed by the public, that the answers they
provided would be treated confidentially and that they could interrupt their participation at
any time. For the above mentioned reasons, and because the study entailed no foreseeable
risks for participants, in was not deemed necessary to seek approval by an ethics committee.
Measures
Participants first provided socio-demographic information (e.g., gender, age, occupation).
After reading a definition of CE, participants completed, for each cognitive enhancer, several
single-item measures we designed. We note that single items assessing general constructs have
comparable test-retest reliability to multi-item scales and comparable predictive validity, are
economical in terms of participant time and burden, and have therefore been recommended
by some authors (e.g., [51–53]). Our predictors were measured for each cognitive enhancer as
follows:
Familiarity. Familiarity with the cognitive enhancers was assessed with the item “Please
indicate your degree of familiarity with the following substances”, scored on a 4 points Likert
scale: 1—I have never heard about this substance, 2—I have heard about this substance but I do
not know its effects, 3—I have heard about this substance and have some knowledge of its effect,
and 4—I have heard about this substance and know a lot about its effects.
Perceived effectiveness. Perceived effectiveness for CE was measured with the item “Do
you think these substances are effective to increase performance?” rated on a Likert scale
(from 1 = Not at all effective to 6 = Absolutely effective). The response “I don’t know” was also
available.
Health risk. Health risk was assessed with the item “Do you think the use of these sub-
stances to increase performance entails risks for the health of the users?” (rated from 1 = Not
at all risky to 6 = Extremely risky). The response “I don’t know” was also available.
Perception of legality. Legal status was assessed by asking participants to classify each
cognitive enhancer in one of 3 categories: “Illegal”, “Legal, with a medical prescription”, “Legal,
sold over-the-counter”. The category “Illegal” was the reference category in our analyses.
Ethical judgement. The criterion variable, ethical judgment was measured for each cogni-
tive enhancer using the following item: “Do you think the use of these substances to increase
performance is ethical (i.e., in accordance with the values of our society)?” (scored from 1 =
Not at all ethical to 6 = Absolutely ethical). The response “I don’t know” was also available.
Data preparation. We restructured the dataset from variables to cases. In other words,
each of the 15 cognitive enhancers for each of the participants became one row of data. From
these observations, we discarded those that were incomplete (listwise deletion), i.e., observa-
tions featuring one or more “I don’t know” answers, or no answers because they could not be
Substance characteristics and ethical judgement towards cognitive enhancement
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included in the analyses. The remaining number of observations was 850, assessed by a total of
148 participants (each assessing on average 5.74 cognitive enhancers, SD = 2.27). Most partici-
pants were able to fully assess only cognitive enhancers of which they knew the effects (the last
two modalities of variable ‘familiarity’ represent 91% of the 850 included observations).
Results
Zero-order correlations between the perceived characteristics of the cognitive enhancers are
provided in Table 1. Ethical judgement correlated significantly with all other studied variables:
positively with familiarity, effectiveness and negatively with health risk (strongest correlation
with ethical judgement: r = .46). The cognitive enhancers that were perceived to be legal
received a more favourable ethical judgement than those that were not, and were considered
less risky. Finally, effectiveness correlated negatively with health risk.
Data were analysed using random intercepts mixed-model regression in R using package
lme4 (random intercepts; maximum likelihood estimation [54]). This allows accounting for
the nesting of observations within both participants and cognitive enhancers which were mod-
eled as crossed factors. Interval variables were group-centred around their mean (by cognitive
enhancer [55]). Doing so allowed us to estimate the impact of our predictors on the assess-
ments of individual cognitive enhancers while excluding variation between cognitive enhanc-
ers and participants. In the null model (Model 1, Table 2), 21% of variance lies at the level of
participants (ICCParticipant in the Null model) and 37% of variance lies at the level of cognitive
enhancers (ICCCE in the Null model).
As can be seen in Table 2, after the inclusion of predictors (Model 2), 22% of residual vari-
ance lied at the level of participants (ICCParticipant in the Model 2) and 31% of residual variance
at the level of cognitive enhancers (ICCCE in the Model 2). The likelihood ratio test (LRT) was
significant, indicating Model 2 fitted the data better than Model 1. The results confirmed all
hypotheses: Familiarity with the effects of the cognitive enhancer (H1, B = 0.27; p = .002), and
its perceived effectiveness for CE (H2, B = 0.12; p = .001) were positively related to positive eth-
ical judgement. The perceived health risk of the cognitive enhancer for the user was negatively
related to ethical judgement (H3, B = -0.36; p< .001). Finally, substances were more favour-
ably assessed in terms of ethical judgement when they were perceived to be legal, compared to
those perceived as being illegal (H4). This effect was stronger for substances perceived as being
legal for sale over-the-counter (B = 1.02; p< .001) compared to those perceived as being legal
with a medical prescription (B = 0.47; p = .041).
Discussion
In the present study, we examined whether and how ethical judgement regarding the use of
cognitive enhancers was related to the perception of four characteristics of cognitive enhanc-
ers. In line with our hypotheses, cognitive enhancers received a more favourable ethical
Table 1. Zero-order correlations among the study variables (N = 850).
M SD 1. 2. 3. 4.
1. Familiarity 3.46 .71 —
2. Effectiveness 2.94 1.66 .029 —
3. Risk 4.17 1.78 -.087 -.334 —
4. Legal .79 .40 .237 -.024 -.449 —
5. Ethical judgement 3.11 2.02 .242 .315 -.634 .462
Correlations above .07 are statistically significant at p < .05. Variable Legal in this table is coded 0 for the legal status “Illegal” and 1 otherwise.
https://doi.org/10.1371/journal.pone.0213619.t001
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judgment when they were perceived as more familiar, more effective, less risky for users’
health, and legal (more so if perceived as sold over-the-counter). [19] found similar results for
health risk, but did not find a significant association with legal status, which may reflect the
lower ecological validity of the vignette method.
Our findings suggest that increasing familiarity (in terms of knowledge) with specific cogni-
tive enhancers (e.g., through portrayal in the media) may render ethical judgments towards
their use more positive (H1), particularly if the emphasis is put on their alleged effectiveness
(H2) and legality (H4) rather than on their risks for health (H3). Furthermore, higher familiar-
ity does not appear to result in increased perceived health risks (see Table 1). Results show that
21% of the variancein ethical judgement is due to differences in participants’ average assess-
ment of the criterion variable (ICCParticipant in the Null model). These results suggest that
inter-individual differences partly explain such a variation.
It has been previously suggested that public opinion should be taken into account in design-
ing CE-related policies because it has reached a sufficient degree of maturity on the topic [56].
Individuals who feel they know more about specific cognitive enhancers might more readily
contribute to such a debate [57]. Our findings showed that higher perceived knowledge of the
effects of cognitive enhancers is associated with a favourable opinion towards cognitive
enhancers. Our secondary findings further suggest that such perceived knowledge is related to
a reduced perception of the health risks associated with CE. It follows that public participation
in policy making might lead to a distortion of the rationality of the decisions because of an
overrepresentation of individuals who perceive fewer health risks attached to CE and are more
favourable to CE.
Table 2. Summary of the mixed-model regression with Ethical judgement as the criterion variable.
Model 1 (null) Model 2
B CI p B CI p
Fixed Parts
Intercept 2.97 2.35 – 3.58 < .001 2.22 1.57 – 2.86 < .001
Familiarity 0.27 0.10 – 0.44 .002
Effectiveness 0.12 0.05 – 0.19 .001
Health risk -0.36 -0.44 – -0.27 < .001
Legal, with prescription 0.47 0.02 – 0.93 .041
Legal, sold over-the-counter 1.02 0.46 – 1.59 < .001
Random Parts
Residual σ2 1.49 1.30
τ00, Participants 0.74 0.61
τ00, CE 1.24 0.86
NParticipant 148 148
NCE 15 15
ICCParticipant 0.21 0.22
ICCCE 0.36 0.31
Observations 850 850
Loglikelihood / LRT (ChiSq) -1495.7 -1432.4 / 126.62 ���
σ2 = observation variance (Level 1), τ00, Participants = Participants intercept variance (Level 2), τ00, CE = Cognitive enhancer intercept variance (Level 2), NParticipant =
Number of participants; NCE = Number of assessed cognitive enhancers; ICCParticipant = Intraclass correlation for participant cluster membership; ICCCE = Intraclass
correlation for cognitive enhancer cluster membership. Loglikelihood / LRT (ChiSq) = Loglikelihood and Likelihood Ratio Test.
���: p< .001
https://doi.org/10.1371/journal.pone.0213619.t002
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The finding that more perceived knowledge is related to lower perceived health risk also
suggests that when discussing CE, public health campaigns, and ideally the press, should focus
first and foremost on health risks in order to maximize prevention [19, 58]. Providing infor-
mation about CE might be counterproductive without an explicit focus on health risks: health
literacy is a major component of public health [59]). Yet, the presentation of facts about CE in
the media is generally selective and inaccurate, since there is an over-reporting of alleged
increases in CE use, a mention of unrealistic benefits of CE, and an under-reporting of health
risks [4]. This might indirectly result in an increased adoption of CE, as (a) individuals adapt
their conduct to their altered perception of the social norm (pluralistic ignorance [60]) and (b)
the ratio of expected costs and benefits is at the heart of their decisional processes [61].
Limitations and further studies
The use of surveys assessing perceptions of cognitive enhancers that actually exist can promote
ecological validity in comparison to the vignette method, but can render studies vulnerable to
a variety of response biases (e.g., social desirability bias), as well as to common method vari-
ance bias [62]. Thus, although [63] has shown that concerns regarding common method vari-
ance bias have been overstated, caution in the interpretation of findings remains important
when using self-report measures. We note that our study might be less subject to common
method variance bias because of the use of mixed-model analyses which allow partialling out
participant variance [55]. Our study employed a cross-sectional design, which limits the possi-
bility of drawing causal inferences. Using a longitudinal design, further studies could examine
whether the use of specific cognitive enhancers [64] predicts additional variance in their ethical
judgement towards their use, and whether perception of health risk, effectiveness, legality and
knowledge about specific cognitive enhancers predict their use.
Conclusion
Our study suggests that individual perceived characteristics of cognitive enhancers influence
people’s ethical judgement towards CE. These findings extend the incipient knowledge about
the factors relating to favourable views of CE. Well-designed prevention campaign should
focus on presenting the health and penal risks of cognitive enhancers, as well as the lack of evi-
dence regarding their effectiveness.
Appendix
A. The list of cognitive enhancers participants were requested to assess is presented below.
These were randomly presented to each participant for each assessed characteristic.
Adderall
Alcohol
Ampakine
Amphetamines
Berocca �
Caffeine (e.g., coffee, tea)
Cocaine
Guanfacine
Magnesium
Methylphenidate (e.g., Ritalin)
Modafinil
Nicotine (e.g., cigarettes)
Piracetam
Substance characteristics and ethical judgement towards cognitive enhancement
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Tonoglutal �
Tyrosine
� Berocca and Tonoglutal are over-the-counter dietary supplements, advertised for their
cognitive enhancing properties, which can be found in most drugstores in Switzerland, where
the study took place
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19. Sattler S, Forlini C, Racine É, & Sauer C. Impact of contextual factors and substance characteristics on
perspectives toward cognitive enhancement. PLoS One. 2013; 8:e71452. https://doi.org/10.1371/
journal.pone.0071452 PMID: 23940757
20. Aguinis H, & Bradley KJ. Best practice recommendations for designing and implementing experimental
vignette methodology studies. Organ Res Methods. 2014; 17:351–71.
21. Hainmueller J, Hangartner D, & Yamamoto T. Validating vignette and conjoint survey experiments
against real-world behavior. P Natl Acad Sci USA. 2015; 112:2395–400.
22. Bohrn IC, Altmann U, Lubrich O, Menninghaus W, & Jacobs AM. When we like what we know–A
parametric fMRI analysis of beauty and familiarity. Brain Lang. 2013; 124:1–8. https://doi.org/10.1016/j.
bandl.2012.10.003 PMID: 23332807
23. Greene J, & Haidt J. How (and where) does moral judgment work? Trends Cogn Sci. 2002; 6:517–23.
PMID: 12475712
24. Moll J, Zahn R, de Oliveira-Souza R, Krueger F, & Grafman J. The neural basis of human moral cogni-
tion. Nat Rev Neurosci. 2005; 6:799–809. https://doi.org/10.1038/nrn1768 PMID: 16276356
25. Berscheid E, & Ammazzalorso H. Emotional experience in close relationships. In Fletcher GJO & Clark
MS, Blackwell handbook of social psychology.Vol. 2. Oxford, UK: Blackwell; 2001. p 308–30.
26. Coupey E, Irwin JR, & Payne JW. Product category familiarity and preference construction. J Consum
Res. 1998; 24:459–68.
27. Carlson JS, & Widaman KF. The effects of study abroad during college on attitudes toward other cul-
tures. Int J Intercult Rel. 1988; 12:1–17.
28. Pettigrew TF, & Tropp LR. A meta-analytic test of intergroup contact theory. J Pers Soc Psychol. 2006;
90:751–83. https://doi.org/10.1037/0022-3514.90.5.751 PMID: 16737372
29. Zajonc RB. Attitudinal effects of mere exposure. J Pers Soc Psychol. 1968; 9:1–27. https://doi.org/10.
1037/h0025716
30. Partridge B, Lucke J, & Hall W. A comparison of attitudes toward cognitive enhancement and legalized
doping in sport in a community sample of Australian adults. A J Bioethics. 2012; 4:81–6.
31. Smart JJC, & Williams B (1973). Utilitarianism: For and against. Cambridge: Cambridge University
Press; 1973.
32. Tobler PN, Kalis A, & Kalenscher T. The role of moral utility in decision-making: An interdisciplinary
framework. Cogn Affect Behav Neurosc. 2008; 8:390–401.
33. Hechter M. The role of values in rational choice theory. Ration Soc. 1994; 6:318–33.
34. Tversky A & Kahneman D. Advances in prospect theory: Cumulative representation of uncertainty. J
Risk Uncertainty. 1992; 5:297–323.
35. Gibson BM, Wasserman EA, & Kamil AC. Pigeons and people select efficient routes when solving a
one-way" traveling salesperson" task. J Exp Psychol Anim Behav Process. 2007; 33:244–61. https://
doi.org/10.1037/0097-7403.33.3.244 PMID: 17620024
36. Loewenstein GF, Thompson L, & Bazerman MH. Social utility and decision making in interpersonal con-
texts. J Pers Soc Psychol. 1989; 57:426–41.
37. Sattler S, Sauer C, Mehlkop G, & Graeff P. The rationale for consuming cognitive enhancement drugs
in university students and teachers. PloS one. 2013; 8:e68821. https://doi.org/10.1371/journal.pone.
0068821 PMID: 23874778
38. Eisenberg AE, Baron J, & Seligman ME. Individual differences in risk aversion and anxiety. Psychol
Bull. 1998; 87:245–51.
39. Zhao J, Harris M, & Vigo R (2016). Anxiety and moral judgment: The shared deontological tendency of
the behavioral inhibition system and the unique utilitarian tendency of trait anxiety. Pers Indiv Differ.
2016; 95:29–33.
40. Conrad P. Wellness as virtue: Morality and the pursuit of health. Cult Med Psychiat. 1994; 18:385–401.
41. Helman CG. Culture, health and illness. 5th ed. London: Hodder Arnold 2007.
Substance characteristics and ethical judgement towards cognitive enhancement
PLOS ONE | https://doi.org/10.1371/journal.pone.0213619 March 14, 2019 9 / 10
42. Rozin P, & Singh L. The moralization of cigarette smoking in the United States. J Consum Psychol.
1999; 8:321–37.
43. Massey JL, & Krohn MD. A longitudinal examination of an integrated social process model of deviant
behavior. Soc Forces. 1986; 65:106–34.
44. Raz J. The authority of law: essays on law and morality. Oxford: Oxford University Press; 2009.
45. Simmonds N. Law as a moral idea. Oxford: Oxford University Press; 2007.
46. Amonini C, & Donovan RJ. The relationship between youth’s moral and legal perceptions of alcohol,
tobacco and marijuana and use of these substances. Health Educ Res. 2005; 21:276–86. https://doi.
org/10.1093/her/cyh064 PMID: 16234282
47. Bilz K, & Nadler J. Law, psychology, and morality. Psychol Learn Motiv. 2009; 50:101–31.
48. Pickett JT, & Baker T. Punishment and solidarity? An experimental test of the educative-moralizing
effects of legal sanctions. J Exp Criminol. 2017; 13:217–40.
49. Tyler TR. Why people obey the law. Princeton: Princeton University Press; 2006.
50. Walker N, & Argyle M. Does the law affect moral judgments?. Brit J Criminol. 1964; 4:570–81.
51. Bergkvist L, & Rossiter JR. The predictive validity of multiple-item versus single-item measures of the
same constructs. J Marketing Res. 2007; 44:175–84.
52. Fisher GG, Matthews RA, & Gibbons AM (2016). Developing and investigating the use of single-item
measures in organizational research. J Occup Health Psych: 21:3–23.
53. Wanous JP, & Hudy MJ. Single-item reliability: a replication and extension. Organ Res Methods. 2001;
4:361–75.
54. Bates D, Maechler M, Bolker B, & Walker S (2014). lme4: Linear mixed-effects models using Eigen and
S4. R package version; 1:1–23.
55. Snijders T, & Bosker R. Multilevel analysis: An introduction to basic and applied multilevel analysis. 2nd
ed. London: Sage; 2012.
56. Fitz NS, Nadler R, Manogaran P, Chong EW, & Reiner PB. Public attitudes toward cognitive enhance-
ment. Neuroethics-NETH. 2014;7, 173:88.
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